Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2011Arthritis & Rheumatism

A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

View Full Paper
Ask AI
Bookmark
Share

Authors

MYMichael YellinIPI.A. PaliienkoABAndra Bălănescu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yellin et al. (2011) studied this question.

synapsesocial.com/papers/6a703c55f44fa9f079ddcfd6https://doi.org/10.1002/art.34330
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Suppression of collagen-induced arthritis by continuous administration of IL-41997 · 165 citations
  2. 2WWW2002 · 1,377 citations
  3. 3High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis2003 · 296 citations
  4. 4CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis2009 · 96 citations
  5. 5Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial2003 · 1,767 citations